interleukin-4
Recombinant proteinexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Dec 23, 1996 (NCT00001564)
Timeline
Indications
Studied for
- HIV Infections · Phase 1
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1/Phase 2
- Leukemia, Myeloid, Acute · Phase 1/Phase 2
- Leukemia, Myeloid, Chronic-Phase · Phase 1/Phase 2
- Lymphoma, Non-Hodgkin · Phase 1/Phase 2
- Melanoma · Phase 2
- Myelodysplastic Syndromes · Phase 1/Phase 2
- Rhabdomyosarcoma · Phase 2
- Sarcoma, Ewing · Phase 2
- Sarcoma, Kaposi · Phase 1
Mechanism of action
- Interleukin-4 receptor subunit alphaSupplementation
IL4R supplementation
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- binetrakin
- il-4
- il-4
- interleukin-4
- interleukin-4
- interleukin 4 human
- interleukin 4 (human)
- interleukin-4 (human; nonglycosylated)
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00923910 | Phase 1/Phase 2 (Phase 2) | Feb 22, 2008 | National Cancer Institute (NCI), National Institutes of Health (NIH) |
| NCT00000769 | Phase 1 | Nov 2, 1999 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00006113 | Phase 2 | Jun 1, 1999 | National Cancer Institute (NCI), University of Southern California |
| NCT00001564 | Phase 2 | Dec 23, 1996 | National Cancer Institute (NCI) |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 3 | 2 | 1 | 1996 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 1 | 1 | 1999 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2008 |
| University of Southern California | Academic/Hospital | 1 | 1 | 1 | 1999 |
4 organizations
Page 1 / 1